Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Immediate Versus Deferred Start of Anti-HIV Therapy in HIV-Infected Adults Being Treated for Tuberculosis (STRIDE)

This study has been completed.
Sponsor:
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
AIDS Clinical Trials Group
ClinicalTrials.gov Identifier:
NCT00108862
First received: April 19, 2005
Last updated: January 4, 2016
Last verified: January 2016
Results First Received: September 27, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: HIV Infection
Tuberculosis
Interventions: Other: Strategy: Immediate ART
Other: Strategy: Deferred ART

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Study participants were recruited at 26 sites from 13 countries: 4 each from U.S. and South Africa; 3 from Brazil; 2 each from Peru, Botswana, Kenya, Malawi, and India; and 1 each from Haiti, Uganda, Zambia, Zimbabwe, and Thailand, between September 2006 and August 2009.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
HIV-infected persons at least 13 years of age, naive to antiretroviral therapy, who had received 1-14 cumulative days of a rifamycin-based TB regimen within 28 days prior to study entry, and had a CD4 count <250 cells/mm3. Randomization was stratified by screening CD4 (<50 vs =>50). Three participants were deemed ineligible and taken off study.

Reporting Groups
  Description
Immediate ART These participants initiated HIV antiretroviral therapy (ART) within 72 hours of randomization, which took place at most 2 weeks after initiating rifampin (RIF)- or other rifamycin-based TB treatment according to in-country national TB treatment guidelines. The study-provided drugs were efavirenz (EFV) 600 mg (provided to non-U.S. sites only; 1 tablet orally) and emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg (1 fixed-dose combination tablet orally) once daily. FTC 200 mg (1 capsule) and TDF 300 mg (1 tablet) could be substituted for the fixed-dose combination tablet and was provided by the study. Participants who could not tolerate EFV could be offered nevirapine (NVP) 200 mg daily for 14 days, then 200 mg twice daily. Substitutions with other locally-available U.S. Food and Drug Administration (FDA)-approved or tentatively approved antiretrovirals (ARVs) that were compatible with TB therapy could be used at the discretion of the site investigator.
Deferred ART These participants deferred ART until 8 to 12 weeks after initiation of their RIF- or other rifamycin-based TB treatment according to in-country national TB treatment guidelines. The study-provided drugs were EFV 600 mg (provided to non-U.S. sites only; 1 tablet orally) and FTC 200 mg/TDF 300 mg (1 fixed-dose combination tablet orally) once daily. FTC 200 mg (1 capsule) and TDF 300 mg (1 tablet) could be substituted for the fixed-dose combination tablet and was provided by the study. Participants who could not tolerate EFV could be offered NVP 200 mg daily for 14 days, then 200 mg twice daily. Substitutions with other locally-available U.S. FDA-approved or tentatively approved ARVs that were compatible with TB therapy could be used at the discretion of the site investigator.

Participant Flow:   Overall Study
    Immediate ART   Deferred ART
STARTED   405   401 [1] 
COMPLETED   337   339 
NOT COMPLETED   68   62 
Death                31                37 
Withdrawal by Subject                10                6 
Lost to Follow-up                27                19 
[1] Three participants who were deemed clinically ineligible and taken off study were omitted.



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Immediate ART These participants initiated HIV antiretroviral therapy (ART) within 72 hours of randomization, which took place at most 2 weeks after initiating rifampin (RIF)- or other rifamycin-based TB treatment according to in-country national TB treatment guidelines. The study-provided drugs were efavirenz (EFV) 600 mg (provided to non-U.S. sites only; 1 tablet orally) and emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg (1 fixed-dose combination tablet orally) once daily. FTC 200 mg (1 capsule) and TDF 300 mg (1 tablet) could be substituted for the fixed-dose combination tablet and was provided by the study. Participants who could not tolerate EFV could be offered nevirapine (NVP) 200 mg daily for 14 days, then 200 mg twice daily. Substitutions with other locally-available U.S. Food and Drug Administration (FDA)-approved or tentatively approved antiretrovirals (ARVs) that were compatible with TB therapy could be used at the discretion of the site investigator.
Deferred ART These participants deferred ART until 8 to 12 weeks after initiation of their RIF- or other rifamycin-based TB treatment according to in-country national TB treatment guidelines. The study-provided drugs were EFV 600 mg (provided to non-U.S. sites only; 1 tablet orally) and FTC 200 mg/TDF 300 mg (1 fixed-dose combination tablet orally) once daily. FTC 200 mg (1 capsule) and TDF 300 mg (1 tablet) could be substituted for the fixed-dose combination tablet and was provided by the study. Participants who could not tolerate EFV could be offered NVP 200 mg daily for 14 days, then 200 mg twice daily. Substitutions with other locally-available U.S. FDA-approved or tentatively approved ARVs that were compatible with TB therapy could be used at the discretion of the site investigator.
Total Total of all reporting groups

Baseline Measures
   Immediate ART   Deferred ART   Total 
Overall Participants Analyzed 
[Units: Participants]
 405   401   806 
Age 
[Units: Participants]
     
<=18 years   0   2   2 
Between 18 and 65 years   403   398   801 
>=65 years   2   1   3 
Age 
[Units: Years]
Median (Inter-Quartile Range)
 34 
 (29 to 40) 
 34 
 (29 to 42) 
 34 
 (29 to 41) 
Gender 
[Units: Participants]
     
Female   139   166   305 
Male   266   235   501 
Region of Enrollment 
[Units: Participants]
     
South Africa   109   112   221 
Malawi   69   68   137 
Brazil   57   56   113 
Kenya   36   36   72 
Peru   23   25   48 
India   26   21   47 
Zambia   17   17   34 
Zimbabwe   16   17   33 
Uganda   15   14   29 
Botswana   13   15   28 
Haiti   12   8   20 
United States   9   10   19 
Thailand   3   2   5 
TB Diagnosis Level at Entry 
[Units: Participants]
     
Confirmed TB   193   181   374 
Probable TB   208   218   426 
Not TB   4   2   6 
Drug-Resistant TB Status at Entry 
[Units: Participants]
     
Rifampin (RIF) Resistant TB   1   0   1 
Isoniazid (INH) Resistant TB   3   5   8 
RIF and INH Resistant TB (Multi-Drug Resistant TB)   1   4   5 
RIF and INH Sensitive TB   400   392   792 
Time to ART Start from Start of TB Medications 
[Units: Days]
Median (Inter-Quartile Range)
 10 
 (7 to 12) 
 70 
 (66 to 75) 
 14 
 (10 to 70) 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Percent of Participants Who Survived Without AIDS Progression.   [ Time Frame: Through week 48 ]

2.  Secondary:   Percent of Participants Reporting a Grade 3 or 4 Adverse Event or Laboratory Abnormality   [ Time Frame: Through week 48 ]

3.  Secondary:   Time to First New AIDS-defining Illness or Death.   [ Time Frame: Through week 48 ]

4.  Secondary:   Percent of Participants With Culture-confirmed Tuberculosis (TB) Who Survived Without AIDS Progression.   [ Time Frame: Through week 48 ]

5.  Secondary:   Percent of Participants Who Interrupted or Discontinued at Least One Tuberculosis (TB) Medication Due to Toxicity.   [ Time Frame: Through week 48 ]

6.  Secondary:   Percent of Participants With Confirmed or Probable Tuberculosis (TB) Whose TB Resolved, or Who Required TB Treatment Through the End of Follow-up, or Died, or Were Lost to Follow-up.   [ Time Frame: Through week 48 ]

7.  Secondary:   Percent of Participants Whose CD4 Increased by at Least 100 Cells/mm^3 Between Baseline and Week 48.   [ Time Frame: Through week 48 ]

8.  Secondary:   Percent of Participants With MTB IRIS.   [ Time Frame: Through week 48 ]

9.  Secondary:   Percent of Participants With HIV IRIS.   [ Time Frame: Through week 48 ]

10.  Secondary:   Percent of Participants Whose HIV Viral Load Was Less Than 400 Copies/mL at Week 48.   [ Time Frame: Through week 48 ]

11.  Other Pre-specified:   Percent of Participants in the Less Than 50 Cells/mm^3 CD4 Stratum Who Survived Without AIDS Progression.   [ Time Frame: Through week 48 ]

12.  Other Pre-specified:   Percent of Participants in the Greater Than or Equal to 50 Cells/mm^3 CD4 Stratum Who Survived Without AIDS Progression.   [ Time Frame: Through week 48 ]


  Serious Adverse Events
  Hide Serious Adverse Events

Time Frame Through week 48
Additional Description No text entered.

Reporting Groups
  Description
Immediate ART These participants initiated HIV antiretroviral therapy (ART) within 72 hours of randomization, which took place at most 2 weeks after initiating rifampin (RIF)- or other rifamycin-based TB treatment according to in-country national TB treatment guidelines. The study-provided drugs were efavirenz (EFV) 600 mg (provided to non-U.S. sites only; 1 tablet orally) and emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg (1 fixed-dose combination tablet orally) once daily. FTC 200 mg (1 capsule) and TDF 300 mg (1 tablet) could be substituted for the fixed-dose combination tablet and was provided by the study. Participants who could not tolerate EFV could be offered nevirapine (NVP) 200 mg daily for 14 days, then 200 mg twice daily. Substitutions with other locally-available U.S. Food and Drug Administration (FDA)-approved or tentatively approved antiretrovirals (ARVs) that were compatible with TB therapy could be used at the discretion of the site investigator.
Deferred ART These participants deferred ART until 8 to 12 weeks after initiation of their RIF- or other rifamycin-based TB treatment according to in-country national TB treatment guidelines. The study-provided drugs were EFV 600 mg (provided to non-U.S. sites only; 1 tablet orally) and FTC 200 mg/TDF 300 mg (1 fixed-dose combination tablet orally) once daily. FTC 200 mg (1 capsule) and TDF 300 mg (1 tablet) could be substituted for the fixed-dose combination tablet and was provided by the study. Participants who could not tolerate EFV could be offered NVP 200 mg daily for 14 days, then 200 mg twice daily. Substitutions with other locally-available U.S. FDA-approved or tentatively approved ARVs that were compatible with TB therapy could be used at the discretion of the site investigator.

Serious Adverse Events
    Immediate ART   Deferred ART
Total, serious adverse events     
# participants affected / at risk   55/405 (13.58%)   44/401 (10.97%) 
Blood and lymphatic system disorders     
Anaemia † 1     
# participants affected / at risk   6/405 (1.48%)   1/401 (0.25%) 
Leukopenia † 1     
# participants affected / at risk   1/405 (0.25%)   0/401 (0.00%) 
Neutropenia † 1     
# participants affected / at risk   1/405 (0.25%)   3/401 (0.75%) 
Cardiac disorders     
Cardiac failure congestive † 1     
# participants affected / at risk   1/405 (0.25%)   1/401 (0.25%) 
Gastrointestinal disorders     
Ascites † 1     
# participants affected / at risk   1/405 (0.25%)   0/401 (0.00%) 
Diarrhoea † 1     
# participants affected / at risk   2/405 (0.49%)   0/401 (0.00%) 
Oesophagitis † 1     
# participants affected / at risk   0/405 (0.00%)   1/401 (0.25%) 
Peritonitis † 1     
# participants affected / at risk   0/405 (0.00%)   1/401 (0.25%) 
Vomiting † 1     
# participants affected / at risk   1/405 (0.25%)   0/401 (0.00%) 
General disorders     
Death † 1     
# participants affected / at risk   2/405 (0.49%)   6/401 (1.50%) 
Pyrexia † 1     
# participants affected / at risk   1/405 (0.25%)   0/401 (0.00%) 
Hepatobiliary disorders     
Hepatitis † 1     
# participants affected / at risk   1/405 (0.25%)   2/401 (0.50%) 
Hepatitis alcoholic † 1     
# participants affected / at risk   1/405 (0.25%)   0/401 (0.00%) 
Hepatotoxicity † 1     
# participants affected / at risk   5/405 (1.23%)   4/401 (1.00%) 
Hyperbilirubinaemia † 1     
# participants affected / at risk   1/405 (0.25%)   1/401 (0.25%) 
Infections and infestations     
Bacterial sepsis † 1     
# participants affected / at risk   1/405 (0.25%)   0/401 (0.00%) 
Gastroenteritis † 1     
# participants affected / at risk   0/405 (0.00%)   2/401 (0.50%) 
Meningitis bacterial † 1     
# participants affected / at risk   1/405 (0.25%)   0/401 (0.00%) 
Meningitis cryptococcal † 1     
# participants affected / at risk   0/405 (0.00%)   3/401 (0.75%) 
Meningitis tuberculous † 1     
# participants affected / at risk   2/405 (0.49%)   1/401 (0.25%) 
Mycobacterium avium complex infection † 1     
# participants affected / at risk   2/405 (0.49%)   1/401 (0.25%) 
Pneumocystis jiroveci pneumonia † 1     
# participants affected / at risk   1/405 (0.25%)   0/401 (0.00%) 
Pneumonia bacterial † 1     
# participants affected / at risk   1/405 (0.25%)   1/401 (0.25%) 
Pulmonary tuberculosis † 1     
# participants affected / at risk   7/405 (1.73%)   1/401 (0.25%) 
Sepsis † 1     
# participants affected / at risk   0/405 (0.00%)   3/401 (0.75%) 
Tuberculoma of central nervous system † 1     
# participants affected / at risk   1/405 (0.25%)   0/401 (0.00%) 
Tuberculosis † 1     
# participants affected / at risk   1/405 (0.25%)   0/401 (0.00%) 
Viral myocarditis † 1     
# participants affected / at risk   1/405 (0.25%)   0/401 (0.00%) 
Injury, poisoning and procedural complications     
Alcohol poisoning † 1     
# participants affected / at risk   1/405 (0.25%)   0/401 (0.00%) 
Gun shot wound † 1     
# participants affected / at risk   1/405 (0.25%)   1/401 (0.25%) 
Investigations     
Aspartate aminotransferase increased † 1     
# participants affected / at risk   1/405 (0.25%)   0/401 (0.00%) 
Blood alkaline phosphatase increased † 1     
# participants affected / at risk   0/405 (0.00%)   1/401 (0.25%) 
Blood creatinine increased † 1     
# participants affected / at risk   1/405 (0.25%)   1/401 (0.25%) 
Neutrophil count decreased † 1     
# participants affected / at risk   0/405 (0.00%)   4/401 (1.00%) 
Metabolism and nutrition disorders     
Hypokalaemia † 1     
# participants affected / at risk   1/405 (0.25%)   0/401 (0.00%) 
Hyponatraemia † 1     
# participants affected / at risk   2/405 (0.49%)   0/401 (0.00%) 
Hypophosphataemia † 1     
# participants affected / at risk   1/405 (0.25%)   3/401 (0.75%) 
Neoplasms benign, malignant and unspecified (incl cysts and polyps)     
Meningioma † 1     
# participants affected / at risk   1/405 (0.25%)   0/401 (0.00%) 
Nervous system disorders     
Central nervous system mass † 1     
# participants affected / at risk   0/405 (0.00%)   1/401 (0.25%) 
Cerebral haemorrhage † 1     
# participants affected / at risk   1/405 (0.25%)   0/401 (0.00%) 
Coma hepatic † 1     
# participants affected / at risk   1/405 (0.25%)   0/401 (0.00%) 
Encephalitis † 1     
# participants affected / at risk   1/405 (0.25%)   0/401 (0.00%) 
Hemiplegia † 1     
# participants affected / at risk   1/405 (0.25%)   0/401 (0.00%) 
Intracranial pressure increased † 1     
# participants affected / at risk   1/405 (0.25%)   0/401 (0.00%) 
Psychiatric disorders     
Completed suicide † 1     
# participants affected / at risk   0/405 (0.00%)   1/401 (0.25%) 
Confusional state † 1     
# participants affected / at risk   1/405 (0.25%)   0/401 (0.00%) 
Renal and urinary disorders     
Renal failure † 1     
# participants affected / at risk   3/405 (0.74%)   0/401 (0.00%) 
Renal failure acute † 1     
# participants affected / at risk   3/405 (0.74%)   2/401 (0.50%) 
Renal impairment † 1     
# participants affected / at risk   2/405 (0.49%)   0/401 (0.00%) 
Respiratory, thoracic and mediastinal disorders     
Dyspnoea † 1     
# participants affected / at risk   0/405 (0.00%)   1/401 (0.25%) 
Epistaxis † 1     
# participants affected / at risk   0/405 (0.00%)   1/401 (0.25%) 
Pulmonary embolism † 1     
# participants affected / at risk   0/405 (0.00%)   1/401 (0.25%) 
Respiratory failure † 1     
# participants affected / at risk   1/405 (0.25%)   0/401 (0.00%) 
Skin and subcutaneous tissue disorders     
Rash † 1     
# participants affected / at risk   2/405 (0.49%)   0/401 (0.00%) 
Vascular disorders     
Shock † 1     
# participants affected / at risk   0/405 (0.00%)   1/401 (0.25%) 
Events were collected by systematic assessment
1 Term from vocabulary, MedDRA 14.0




  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information